NASDAQ$CGEM
Cullinan Oncology Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Announced financial results for the third quarter ended September 30, 2021.
Cullinan Oncology reported a net loss of $18.3 million and held $445.4 million in cash, cash equivalents, and investments as of September 30, 2021. The company is advancing its pipeline, with clinical updates for Cullinan Pearl expected in Q4 2021 and plans to advance Cullinan MICA and Cullinan Florentine into clinical trials by year-end.
- Cullinan Pearl clinical update planned for Q4 2021.
- Cullinan MICA and Cullinan Florentine programs to advance into clinical trials by year end 2021.
- Cash and investments of $445.4 million as of September 30, 2021.
- Net loss for the quarter was $18.3 million.
Headline financials
Revenue & EPS history
Cullinan Oncology · Revenue · Quarterly
$18.9M
Forward guidance
This press release contains forward-looking statements regarding Cullinan’s beliefs and expectations regarding our preclinical and clinical development plans, clinical trial designs, clinical and therapeutic potential, and strategy of our product candidates.
Tailwinds
- Timing and success of planned preclinical and clinical development of programs, including for CLN-081, CLN-619, and CLN-049.
- Timing and success of planned regulatory submissions.
- Expectations and beliefs around the safety and activity of CLN-081 in Phase 1/2a trial.
- Ability to evaluate strategic opportunities to accelerate development timelines.
- Presentation of additional data at upcoming scientific conferences in 2021.
Headwinds
- Uncertainty regarding the timing and results of regulatory submissions.
- Success of clinical trials and preclinical studies.
- Risks related to ability to protect and maintain intellectual property position.
- Risks related to manufacturing, supply, and distribution of product candidates.
- Risk that results of preclinical studies or clinical studies will not be predictive of future results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-2.1%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+13.5%
Q1 2022
Best reaction
-10.8%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | +7.7% | -10.0% | |
| Q3 2025 | +0.8% | +6.7% | +44.9% | |
| Q2 2025 | -10.8% | -7.7% | -11.3% | |
| Q1 2025 | +2.3% | +1.3% | +5.8% | |
| Q4 2024 | +1.9% | -3.8% | -5.1% | |
| Q3 2024 | -2.8% | -2.8% | -20.8% | |
| Q1 2024 | -9.7% | -9.1% | -28.4% | |
| Q4 2023 | -6.2% | -8.7% | -1.8% | |
| Q3 2023 | -2.7% | -11.1% | -17.7% | |
| Q2 2023 | +4.3% | -1.4% | -0.6% | |
| Q1 2023 | +1.2% | -5.3% | +36.0% | |
| Q4 2022 | -1.5% | +3.3% | -9.1% | |
| Q3 2022 | +3.8% | +1.0% | -3.0% | |
| Q2 2022 | -5.6% | +0.8% | -3.5% | |
| Q1 2022 | +13.5% | +6.8% | +12.1% | |
| Q4 2021 | +8.8% | +3.0% | -8.6% | |
| Q3 2021 | -4.5% | -10.1% | -28.8% | |
| Q2 2021 | +7.8% | +3.8% | +8.0% | |
| Q1 2021 | +2.2% | +12.4% | +13.1% | |
| Q4 2020 | +9.5% | +8.4% | -13.9% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro